New resource: The MVEC Conversation: myocarditis/pericarditis following mRNA vaccines​

继我们的 CVU 迷你虚拟活动之后: 心脏问题:与 COVID-19 mRNA 疫苗接种相关的心肌炎和心包炎, 墨尔本疫苗教育中心很高兴地宣布我们的最新资源 MVEC 对话:mRNA 疫苗后的心肌炎/心包炎。 

该视频播客深入探讨了这一特殊关注的不良事件 (AESI),特邀嘉宾 Tom Shimabukuro 博士是佐治亚州亚特兰大疾病控制与预防中心 (CDC) 免疫安全办公室副主任,与 Daryl Cheng 博士和 Nigel Crawford 副教授的对话。

To find out more about this resource, please visit our MVEC Events page.


可用于护士免疫课程的英联邦资助名额

具有一年临床经验的注册护士 (RN) 名额有限,可以免费完成联邦资助的护士免疫程序短期课程(有条件)。

免疫接种(Nurse immuniser)短期课程是基于  国家卫生专业人员免疫教育框架 (2017) 并已获得国家健康教育机构的认可 澳大利亚健康教育服务 (HESA).

要了解有关本课程的更多信息,请单击下面的链接。请注意一些分配已经用完。
墨尔本大学:免疫接种(Nurse immuniser)短期课程
基准组免疫认可途径


8 月 30 日 CVU mini 的录音现已发布

Thank you to all who attended our recent CVU miniseries event 心脏问题:与 COVID-19 mRNA 疫苗接种相关的心肌炎和心包炎 on 30th August 2021.

This interactive webinar took an in-depth look at an important vaccine safety signal associated with COVID-19 mRNA vaccines (Pfizer and Moderna).

A recording of this event is now available via our education portal.

To access this recording please follow the link below:

CVU mini - 30th August 2021


MVEC animation: Myocarditis, pericarditis and COVID-19 vaccines

MVEC have created a new animation to help explain myocarditis and pericarditis which have been reported in a small number of individuals who have received mRNA 2019冠状病毒病疫苗 Comirnaty™ 和 Moderna.

To view the animation and to find out more information, please refer to our myocarditis, pericarditis following COVID-19 mRNA vaccines immunisation reference page:
MVEC animation: Myocarditis and pericarditis following COVID-19 mRNA vaccines


Federal Government Announces No Fault COVID-19 Indemnity Scheme

Federal Health Minister Greg Hunt has announced the details of the no fault COVID-19 Vaccine Claim Scheme following extensive consultation with the peak medical, healthcare, business and insurance sectors to ensure a comprehensive National Scheme.

The purpose of the Scheme will be to provide Australians with quick access to compensation for COVID-19 claims related to the administration of a Therapeutic Goods Administration approved COVID-19 vaccine delivered through a Commonwealth Government approved program.

From 6 September Australians who suffer injury and loss of income due to their COVID-19 vaccine will be able to register their intent to claim from the COVID-19 vaccine claims scheme webpage.

要了解更多信息,请点击以下链接:
Federal Government Announcement: No Fault COVID-19 Indemnity Scheme


FDA news release: FDA Approves First COVID-19 Vaccine

The US Food and Drug Administration (FDA) has granted full approval of Pfizer-BioNTech COVID-19 vaccine for individuals 16 years of age and above. The mRNA vaccine was first approved under emergency use authorisation back in December 2020, and is currently the first and only COVID-19 vaccine to receive full authorisation for use.

Pfizer CEO Albert Bourla said in a statement the FDA's approval "affirms the efficacy and safety profile of our vaccine at a time when it is urgently needed."

All FDA-approved vaccines undergo a rigorous standard process for reviewing the quality, safety, and effectiveness. For Comirnaty, new clinical data is used in conjunction with existing information submitted during the initial EUA stage. The FDA’s approval process concluded that the vaccine was 91% effective in preventing COVID-19 disease based on the evaluation of approximately 20,000 vaccine recipients as well as 20,000 placebo recipients aged 16 years and above. Furthermore, to better assess the long term safety outcomes, approximately 12,000 recipients were monitored for an additional 6 months following their second dose of the vaccine. Conclusively, results suggest that the vaccines show an increased risk of myocarditis and pericarditis, particularly among males under the age of 40, following their second jab. The FDA and Centers for Disease Control and Prevention along with the company will continue to monitor the safety and effectiveness of the Comirnaty vaccines, to ensure any concerns continue to be identified and evaluated in a timely manner.

To read the full article, click on the link below:
https://www.fda.gov/news-events/press-announcements/fda-approves-first-covid-19-vaccine


CVU mini event 30th August 2021 - Reminder to register

A reminder to register for our next Clinical Vaccinology Update (CVU) mini event: 心脏问题:与 COVID-19 mRNA 疫苗接种相关的心肌炎和心包炎 on Monday 30th August 2021, at 7pm AEST.

To view the full program and to register for this event, please visit our Events page.

A recording of 心脏问题:与 COVID-19 mRNA 疫苗接种相关的心肌炎和心包炎 will be available on our 教育门户 following the event.


Healthed lecture series featuring Associate Professor Nigel Crawford

MVEC’s Associate Professor Nigel Crawford delivered the COVID-19 Update as part of the recent Healthed Australia online lecture series.

In this lecture, A/Prof Nigel Crawford discussed the following:

  • The role of ATAGI and its relevance to the current pandemic
  • Overview of the newly available Moderna vaccination
  • Rationale and evidence behind the upcoming push for vaccinating children 12 yrs of age and older
  • Update on the clinical features and management pathways for Pfizer-related myocarditis, pericarditis
  • AZ-related clots
  • Lessons learnt from other countries dealing with the Delta pandemic

To listen to the lecture in full, click on the link below:
Healthed lecture series 18th August: COVID Update


八月 CVU 迷你活动现已开放报名

The next Clinical Vaccinology Update (CVU) miniseries event, 心脏问题:与 COVID-19 mRNA 疫苗接种相关的心肌炎和心包炎, will be held virtually on Monday 30th August 2021.

We are excited to welcome our panel who will take an in-depth look at an important vaccine safety signal associated with COVID-19 mRNA vaccines (Pfizer and Moderna), myocarditis and pericarditis. The session will also include a live Q&A panel with experts from the medical, consumer (Heart Foundation) and vaccine safety domains.

Further details can be found via our Events page and the link below:

CVU mini: August 30th 2021


Updated MVEC reference page: COVID-19 vaccination in children

We have updated our COVID-19 vaccination in children page to reflect the statement by the Australian Technical Advisory Group on Immunisation (ATAGI) regarding vaccination of adolescents aged 12-15 years.

The following groups of children among those aged 12–15 years are to be prioritised for vaccination using the Comirnaty (Pfizer) vaccine:

  • Children with specified medical conditions that increase their risk of severe COVID-19 (including severe asthma, diabetes, obesity, cardiac and circulatory congenital anomalies, neuro developmental disorders, epilepsy, immuno-compromised and trisomy 21)
  • Aboriginal and Torres Strait Islander children aged 12–15 years
  • All children aged 12–15 years in remote communities, as part of broader community outreach vaccination programs that provide vaccines for all ages (≥12 years).

To find out more information, please refer to our dedicated MVEC COVID-19 vaccination in children page in the link below.
MVEC COVID-19 vaccination in children page


关于 MVEC

墨尔本疫苗教育中心 (MVEC) 是一个教育网站,旨在为医疗保健专业人员和公众提供最新的免疫接种信息。我们位于研究机构默多克儿童研究所 (MCRI),隶属于维多利亚疫苗安全服务机构 SAEFVIC(社区接种疫苗后的不良事件监测)。